durvalumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
pharma · Respiratory Syncytial Virus Infections · Asthma
MedImmune
MedImmune drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Gaithersburg, USA HQ
1987 Founded
896 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Gaithersburg, USA
- Founded
- 1987
- Employees
- 896
- Programs
- 9
- Drugs
- 7
- Patents
- 0
MedImmune pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
MedImmune drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
influenza vaccine (h1n1)v (split virion, inactivated, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in MedImmune's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in MedImmune's portfolio.
-
palivizumab
Antiinfectives for systemic use (J06)US regulatory status: approved. Molecular target: Fusion glycoprotein F0.
- Target
- Fusion glycoprotein F0
- Mechanism
- Fusion glycoprotein F0 inhibitor
-
Development asset linked to MedImmune in public FDA and regional records.
-
tralokinumab
Dermatologicals (D11)US regulatory status: approved. Molecular target: Interleukin-13.
- Target
- Interleukin-13
- Mechanism
- Interleukin-13 inhibitor